Business Description
Abivax SA
ISIN : US00370M1036
Share Class Description:
HAM:2X10: ADRTotal Employee Number:
69Compare
Compare
Traded in other countries / regions
ABVX.FranceABVX.USA0RA9.UK2X1.GermanyABVX.Austria IPO Date
2026-01-14Description
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 339.7 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -15.7 | |||||
3-Year EPS without NRI Growth Rate | -14.9 | |||||
3-Year FCF Growth Rate | 6.5 | |||||
3-Year Book Growth Rate | 162.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 58.47 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 556.86 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 68.59 | |||||
9-Day RSI | 69.46 | |||||
14-Day RSI | 65.9 | |||||
3-1 Month Momentum % | -15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.25 | |||||
Quick Ratio | 8.25 | |||||
Cash Ratio | 7.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -52.1 | |||||
Shareholder Yield % | 0.58 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -123.85 | |||||
ROA % | -80.24 | |||||
ROIC % | -353.82 | |||||
3-Year ROIIC % | 901.17 | |||||
ROC (Joel Greenblatt) % | -14512.17 | |||||
ROCE % | -91.19 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 22.54 | |||||
Price-to-Tangible-Book | 23.94 | |||||
EV-to-EBIT | -33.78 | |||||
EV-to-EBITDA | -33.91 | |||||
EV-to-FCF | -56.87 | |||||
| Price-to-Net-Current-Asset-Value | 24.46 | |||||
| Price-to-Net-Cash | 25.89 | |||||
Earnings Yield (Greenblatt) % | -2.96 | |||||
FCF Yield % | -1.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Abivax SA Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -4.49 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 65.9 | ||
| 14-Day ATR (€) | 5.309755 | ||
| 20-Day SMA (€) | 97.075 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 64 - 133 | ||
| Shares Outstanding (Mil) | 87.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Abivax SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Abivax SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-12-14 | In 158 days | ||
| Second quarter earnings results for 2026 | 2026-09-14 | In 67 days | ||
| Abivax ABTECT Part-2 Results | 2026-06-30 16:30 | 82.50 (+0.00%) | ||
| ABTECT Maintenance Results Investor Webcast | 2026-06-02 16:30 | 112.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-22 | 103.00 (+0.00%) | ||
| General meeting for 2026 | 2026-05-11 15:00 | 106.00 (+0.00%) | ||
| Annual report for 2025 | 2026-03-23 | 105.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-23 | 105.00 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-12-15 | -- | ||
| Abivax Management Call to Discuss Late-Breaking Abstract at UEG Conference | 2025-10-06 09:00 | -- |
Show
Entries
Abivax SA Frequently Asked Questions
What is Abivax SA(HAM:2X10)'s stock price today?
The current price of HAM:2X10 is €124.00. The 52 week high of HAM:2X10 is €133.00 and 52 week low is €64.00.
When is next earnings date of Abivax SA(HAM:2X10)?
The next earnings date of Abivax SA(HAM:2X10) is 2026-09-14.
Does Abivax SA(HAM:2X10) pay dividends? If so, how much?
Abivax SA(HAM:2X10) does not pay dividend.
Press Release
Articles on Abivax SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers